GREY:IPHAF - Post by User
Comment by
nowayouton Aug 26, 2005 2:49am
88 Views
Post# 9465620
RE: One More criticism of BM Drug
RE: One More criticism of BM Drug"The most important finding, Dr. Larsen noted, was a decreased risk of chronic allograft nephropathy, which affected 44% of patients receiving cyclosporine, but only 20% of those taking low-intensity belatacept and 28% of those taking high-intensity belatacept, which was significant."
Well what's been the Effect of ISA247 on renal function in the psoriasis trials? Hasn't it been statistically insignificant? That's likely better than 20%.
Is the sky really falling? Or are we just seeing the usual Biotech sag in times of no news. Some of the posters on this board have changed their colors pretty fast, wouldn't you say, Irving?